Avecho Biotechnology (ASX:AVE) Total Equity: A$1.56 Mil (As of Dec. 2025)


What is Avecho Biotechnology Total Equity?

Avecho Biotechnology ASX:AVE Total Equity is A$1.56 Mil as of Dec. 2025. The stock has 2 warning signs investors should review.

Avecho Biotechnology's total equity for the quarter that ended in Dec. 2025 was A$1.56 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Avecho Biotechnology Total Equity Historical Data

* Premium members only.

The historical data trend for Avecho Biotechnology's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avecho Biotechnology Total Equity Chart

Avecho Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.54 2.45 6.38 3.27 1.56

Avecho Biotechnology Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.38 4.22 3.27 0.83 1.56

Avecho Biotechnology Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Avecho Biotechnology's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=7.106-5.546
=1.56

Avecho Biotechnology's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=7.106-5.546
=1.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of A$1.56 Mil mean?
Avecho Biotechnology (ASX:AVE) has a Total Equity of A$1.56 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Avecho Biotechnology and its competitors.
Is Avecho Biotechnology's Total Equity too high?
Avecho Biotechnology's current Total Equity is A$1.56 Mil.
How does Avecho Biotechnology's Total Equity compare to VRTX and REGN?
Avecho Biotechnology's Total Equity of A$1.56 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Avecho Biotechnology and its competitors. Avecho Biotechnology's current Total Equity is A$1.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avecho Biotechnology stock overvalued right now?
Avecho Biotechnology (ASX:AVE) has a current Total Equity of A$1.56 Mil. The current Total Equity is A$1.56 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Avecho Biotechnology (ASX:AVE), the current Total Equity is A$1.56 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avecho Biotechnology Business Description

Other Exchanges OEZ:Germany
Address Unit A8, 2A Westall Road, Clayton, Melbourne, VIC, AUS, 3168
Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sales, and licensing of products incorporating its patented platform technology Tocopheryl Phosphate Mixture (TPM), for the pharmaceutical, skincare, and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches, including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.